OCT 19, 2020 8:16 AM PDT

Using qPCR to Diagnose Common Cancer Mutations in Lung Cancer

WRITTEN BY: Jasper Cantrell

Cancer is a disease characterized by DNA mutations. These mutations, while sometimes small, can cause havoc in a cell’s regulatory systems. If a mutation occurs in the right protein at the right time, cancer is likely to result.

Many cancers have what is called a “gain of function” mutation. This means that a protein undergoes a mutation that increases its activity or obtains a wholly different function in rare cases. When this type of mutation occurs, it usually leads to unregulated activation of the mutated protein’s pathway. Researchers use this knowledge and decades of research to create drugs targeted at these critical gain of function mutations.

One common target for lung and other cancers is the BRAF signaling pathway. This pathway is named after the kinase BRAF and normally regulates cellular proliferation, growth, and differentiation. Systems like this are usually heavily regulated, so when a gain of function mutation occurs, it can lead to uncontrolled cell growth. If this mutation occurs in a cancer cell, cancer becomes “aggressive” and far more dangerous.

BRAF mutations occur in a variety of cancers, from lung cancer to skin cancer. Its relatively well-researched background has made it a common biomarker to test against. Biomarkers are biological indicators that can diagnose a patient or obtain their prognosis. The most common biomarker test is an immunohistochemistry test, which essentially stains a tissue sample for a particular protein. In a new study, a team from the Chang Gung Memorial Hospital in Taiwan designed a highly sensitive RT-qPCR (real-time quantitative PCR) test that could identify the common BRAF V600E mutation it could help improve the accuracy of current tests.

RT-qPCR is a sort of DNA scanning method. It uses a guide called a primer to read off and exponentially replicate the target gene so researchers can see something as small as a single mutation. In this case, the primers were designed to identify two common BRAF V600E DNA mutations. The team tested their RT-qPCR test on 306 lung cancer patients and found two patients positive for the mutation. These findings were confirmed using the standard immunohistochemical tests. They also confirmed this on 6 other cancer specimens, confirming that the RT-qPCR method could indeed identify BRAF V600E positive cancers.

While the RT-qPCR method outlined in this study didn’t outperform the immunohistochemical tests, it does a few things right. Immunohistochemical tests can sometimes give false readings due to off-target binding. It is also qualitative data (visual) rather than quantitative (numerical), which can cause bias in data analysis. A big issue is that a primer needs to be designed for each possible mutation, which would make this method quite hard for some of the more diverse mutations out there.

The study concludes, “In summary, a highly sensitive and BRAF V600E/K mutation-specific RT-qPCR was established for detection of BRAF V600E/K mutation and results found low incidence of the BRAF V600E mutation in the lung cancer population of southern Taiwan.”

Sources: Nature Scientific ReportsEuropean Society for Medical Oncology

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
AUG 18, 2021
Technology
Tracking System Maps How Cancer Cells Evolve, Providing New Treatment Insights
AUG 18, 2021
Tracking System Maps How Cancer Cells Evolve, Providing New Treatment Insights
All cells in a tumor share some genetic similarities, but also have key differences, often hindering effective treatment ...
OCT 04, 2021
Cancer
Predicting Progression-Free Survival in a Melanoma Study
OCT 04, 2021
Predicting Progression-Free Survival in a Melanoma Study
IsoPlexis’ Single-Cell Proteomics Predict Progression-Free Survival in Melanoma Study While advancements in oncolo ...
SEP 18, 2021
Genetics & Genomics
Cancer Genes Might Aim for the Immune System, Not Growth Promotion
SEP 18, 2021
Cancer Genes Might Aim for the Immune System, Not Growth Promotion
The DNA in our cells can accumulate damage over may years. Environmental influences like UV light or cigarette smoke may ...
OCT 07, 2021
Cancer
Dual Threat: CAR T Cells Modified to Target Two Neuroblastoma Antigens
OCT 07, 2021
Dual Threat: CAR T Cells Modified to Target Two Neuroblastoma Antigens
Neuroblastoma is a cancer of immature nerve cells found in various areas, including the adrenal glands, neck, chest ...
OCT 14, 2021
Cancer
Mechanism of Resistance to Colorectal Cancer Treatment Uncovered
OCT 14, 2021
Mechanism of Resistance to Colorectal Cancer Treatment Uncovered
Colorectal cancer develops when a series of changes occur across multiple genes.  While researchers have paid signi ...
OCT 14, 2021
Clinical & Molecular DX
Weighing Cancer Cells Helps Predict Treatment Outcomes
OCT 14, 2021
Weighing Cancer Cells Helps Predict Treatment Outcomes
Not all cancer patients respond to oncology treatments in the same way. Some might show signs of improvement as the ther ...
Loading Comments...